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ABSTRACT 
 
 
 
Background: We have observed increased number of "IgE-armed" mast cells in duodenal 
mucosa of patients with food hypersensitivity, and therefore we wanted to explore whether 
serum total IgE levels and atopic sensitization is associated with food-related gastrointestinal 
(GI) complaints. 
 
 
 
 
Methods: Levels of serum total and specific IgE and GI complaints were measured in 161 
patients referred to Section of Clinical Allergology, Haukeland University Hospital, and in a 
general population sample of 479 persons participating in the Bergen ECRHS. Standard inhalant 
and food allergens were measured in the patient group, and inhalant allergens of 
Dermatophagoides pteronyssinus, cat and grass were analyzed in the general population sample. 
All participants filled out two questionnaires, i.e. irritable bowel syndrome (IBS)-Symptom 
Severity Scale (IBS-SSS) and IBS-Symptom Questionnaire (IBS-SQ), to assess their GI 
complaints. Statistical analyzes included bivariate analyzes and multiple regression models. 
 
 
 
 
Results: Total IgE was a significant predictor of GI complaints in a total study population (b = 
 
.037, p = .001). This was found in the general population (b = .038, p = .005), but did not reach 
statistical significance in the patient group. Atopic sensitization was inversely associated with GI 
complaints in both groups, the association was significant in the patient group (b = -77.216, p = 
.001), but not in the general population. Total IgE and atopic sensitization could together explain 
 
6.2 % of the total variance in GI complaints in the patient group and 1.9 % in the general 
population. The association of total IgE with GI complaints was consistent among atopic and 
non-atopic persons, men and women, and across age groups, and no interaction was found by 
atopic status, sex or age. 
 
 
 
 
Conclusion: Serum total IgE was positively associated with GI complaints, while specific IgE 
was inversely associated with GI complaints. Together, total IgE and atopic sensitization could 
explain a relatively small proportion of the total variance in GI complaints. The biological 
mechanisms of food-related GI complaints involving total IgE, but not specific atopic 
sensitization, warrants further studies. 
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1. INTRODUCTION 
 
 
 
Self-reported food hypersensitivity (SFH) is a common condition among the general population 
in western societies and a primary cause of functional gastrointestinal (GI) complaints and 
reduced quality of life (1). Approximately 35% of western inhabitants report intestinal 
hypersensitivity reactions related to consumption of one or more food items. However, only 1- 
3% of these incidents are medically diagnosed as IgE-mediated allergic reactions, and more than 
90% have irritable bowel syndrome (IBS) (2). This unexplained inconsistency between 
subjective and medically confirmed food hypersensitivity is frequently observed and a major 
source of frustration among patients and medical personnel, due to limited diagnostic methods 
and treatment possibilities. Further investigations are necessary to elucidate the pathological 
mechanisms of SFH and thus be able to provide proper treatment for these patients. A recent 
study in atopic patients revealed a strong correlation between elevated serum total 
immunoglobulin E (IgE) levels and number of mast cells with adherent IgE in duodenal mucosa, 
thus proposing a potential triggering effect of “IgE-armed” mast cells on the intestinal immune 
system in SFH patients (3). Additionally, the study also documented an increased intestinal 
permeability in atopic patients compared to non-atopic patients. The presence of similar 
histological changes and intestinal dysfunction is also observed in previous studies in patients 
with atopic diseases, such as dermatitis, eczema, birch pollen allergy, asthma or allergic rhinitis, 
indicating an association between elevated specific IgE-levels and the GI manifestations 
observed in patients with functional GI disorders (4-7). Hence, this proposal will focus on 
whether total IgE levels or atopic sensitization are associated with food-related GI complaints. 
 
This master thesis is developed in compliance with the interdisciplinary MAI team (“Matallergi 
og Intoleranse”, Norwegian translation for food allergy and intolerance) dedicated to the 
investigation of adult patients presented with GI complaints self-attributed to food 
hypersensitivity. This team was established at Haukeland University Hospital (HUH) in 2001 
and consists of specialist doctors in allergology, gastroenterology and psychiatry, as well as 
dietician, psychologist, nurses and research fellows. After 2011, the team investigation program 
was modified. 
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1.1 Food hypersensitivity 
 
 
 
 
Food hypersensitivity is highly prevalent in the Western population. It is a general term 
commonly used to describe a person's abnormal reactions to food. The most frequently food 
items reported as hypersensitive stimuli are cow's milk, wheat, fruits, vegetable, hen's egg, 
peanuts and seafood (8). The symptoms typically affect the GI tract, but other organ systems can 
also be involved. According to the last position paper by the European Academy of Allergology 
and Clinical Immunology (EAACI), the term of food hypersensitivity is used as an overarching 
term to cover all kinds of adverse reactions to food (9). Food hypersensitivity reactions can be 
categorized into allergic and non-allergic hypersensitivity reactions as illustrated in figure 1. 
 
 
 
 
 
 
 
Figure 1: Food hypersensitivity nomenclature. Illustration by 
Gülen Arslan Lied. 
 
 
 
 
 
 
1.1.1 IgE-mediated food allergy 
 
 
 
IgE-mediated allergic reactions involve an immediate type I reaction, with mast cell 
degranulation when these are exposed to antigens attached to antibodies (usually IgE) and 
subsequent production and release of inflammation mediators like histamine, tryptase and 
eosinophil cationic protein (ECP) from sensitized immune effector cells, i.e. degranulated mast 
cells, basophils and eosinophils (10-12). Symptoms occur between a couple of minutes and two 
hours. The released mediators initiate a rapid immunological response which can cause a variety 
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of allergic responses, including GI symptoms. Immediate GI hypersensitivity, oral allergy 
syndrome, acute urticaria, angioedema, acute bronchospasm and allergic rhinitis are the main 
food allergic disorders, which occur by IgE-mediated mechanisms. The most common allergy 
symptoms related to the GI tract are abdominal pain, nausea, vomiting, diarrhea and abdominal 
distention (13, 14). 
 
 
 
1.1.2 Non-IgE mediated food allergy 
 
 
 
Non-IgE mediated allergic responses involve a much slower cell-mediated reaction, type III or 
IV, and are usually more difficult to diagnose (15). Reactions can occur within two to 48 hours 
(late phase reactions), and the initiated immune reactions occur in the absence of IgE. Hence, 
immunologically sensitized lymphocytes may play a major role. Non-IgE mediated food allergy 
comprises abnormal reactions in gut generating diverse GI symptoms caused by immunologic 
responses to contributory food proteins (16). Celiac disease, dietary protein (food-induced) 
proctitis, enterocolitis and enteropathy are some of the examples of GI diseases related with non- 
IgE-mediated food allergy (16). 
 
 
 
 
1.1.3 Non-allergic food hypersensitivity 
 
 
 
Non-allergic food hypersensitivity comprises much more heterogeneous mechanisms, such as 
enzyme deficiency (lactose intolerance) or malabsorption in gut, resulting in GI dysfunction and 
often diverse extra-intestinal symptoms. The state is complex and difficult to diagnose, and 
comprehensive diagnostic methods are occasionally used to identify the problems (11, 17). 
Patients reporting non-allergic food hypersensitive reactions are often difficult to diagnose due to 
their subjective complaints and the presence of functional symptoms that are difficult to 
objectively measure. Not being able to give an accurate diagnose causes great frustration among 
these patients, who often feel that they are being neglected by health professionals, given that 
they do not have a "true" food allergy (15). The situation also results in aggravation for the 
physicians and other health care personnel who are not capable of provide effective treatment for 
these patients. 
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1.1.4 Irritable bowel syndrome 
 
 
 
Patients with SFH often have symptoms analogous to IBS complaints and more than 90 % of 
them are diagnosed as IBS after examination (figure 2) (1, 15, 18). IBS is a functional GI 
disorder that causes a whole range of various symptoms, whereas abdominal pain and 
discomfort, bloating and altered bowel habits lasting more than 6 months are the main symptoms 
triad for IBS. The diagnosis is based on exclusion of any organic causes of GI symptoms and 
fulfilling the criteria of Rome III consensus. There are no acknowledged biochemical assays or 
clinical measurements to aid diagnosis. The outbreak of IBS symptoms tends to decrease with 
aging, and there are more women than men reporting IBS. People suffering from IBS often 
report that the condition prevents them from everyday life and contributes to reduced quality of 
life. On average, those affected by the condition absent from work up to 17 days per year, 
corresponding almost the same absence caused by colds (15, 19). Also, amongst patients who are 
highly affected by the symptomatic aspects, some may quit their jobs due to impaired quality of 
life and severe depression (1). 
 
 
 
 
 
 
 
 
 
 
Figure 2: More than 90 % of patients with self-reported food hypersensitivity are diagnosed with IBS after 
examination. Illustration by author. 
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1.2 Symptoms 
 
 
 
Food-related GI complaints are extensive and often nonspecific. The symptoms are not uniform 
and can occur in different degrees and at different time periods. Alternating bowel habits, often 
with diarrhea as predominant, abdominal pain or discomfort, cramps, flatulence and bloating are 
the most common complaints, which are also consistent with IBS symptoms. It is commonly 
observed in these patients that discomfort is less prominent in the morning, but exacerbates 
during daytime. Many experience symptom relief after defecation and frequent bowel 
movements several times during the day are not uncommon (1, 15, 18). However, feces at night 
occur rarely in patients with functional GI complaints unlike patients with inflammatory bowel 
disease, such as Crohn`s disease or ulcerative colitis. 
 
Many patients with SFH find themselves producing extra amounts of intestinal gas, beyond the 
usual. However, further research has shown that these patients do not necessarily always produce 
more intestinal gas than healthy subjects, but they are much more sensitive to the excess air 
formed. This sort of gut hyperalgesia due to gaseous distention is highly recognized in patients 
with IBS, and is a major key factor contributing to GI complaints. These patients often 
experience intestinal gas retention and difficulty getting air out (20-22). There may be several 
explanations for this, whereas emotional problems and stress are the most prominent. Chronic or 
acute stress may alter gut motility and cause muscle tension, which makes it difficult to relax in 
bowel. Nevertheless, whilst abundant amounts of gas are the genuine issue, it is conceivable that 
the problematic air might be related to excessive bacterial fermentation in colon. Patients with 
functional GI disorders have an abnormal composition of the bacterial flora, and a change in the 
micro flora has been shown to affect intestine motility and increase the amount of gas produced 
(20, 21, 23). 
 
The condition also affects other organ systems than the gut. Typical SFH patients also 
encompass extra-intestinal health complaints, and Lind et al. demonstrated in 2005 a clear 
association between subjective health complaints and SFH. The incidence of systemic 
symptoms, such as muscle and joint pains, and the prevalence of anxiety and depression are 
often high among SFH patients (24). In addition, Berstad and colleagues reported that patients 
with perceived food hypersensitivity often suffer from chronic fatigue and fibromyalgia, in 
which they described as food-induced triad. These conditions are often persistent and at least as 
serious as the digestion-related issues (20, 24, 25). Many of the patients with SFH and IBS also 
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experience milder forms of dyspepsia and reflux symptoms such as heartburn and acid 
regurgitate. 
 
Most patients with SFH determinedly believe they react to one or more food items, even though 
blood tests and skin prick tests are normal. Thus, selected food items are often avoided or totally 
excluded in diet. Many patients are worried and anxious about which food they can and cannot 
eat, and due to indiscriminate food avoidance many patients suffering from SFH are often under- 
or malnourished (17). In addition, anxiety might activate complex neurological networks 
resulting in cognitive emotional sensitization, which contributes to excessive preoccupation of 
food and food-related pain and complaints. Above a certain threshold level, the activation of 
these networks might lead to greater perception of symptoms (24). The patients thus deceive 
themselves and believe that they react to selected food items even though in reality they do not. 
Gluten and dairy products are food items frequently reported as symptom triggers and also the 
products SFH patients typically avoid the most. Hence, these patients are at risk of not getting 
proper and adequate nourishment (11). 
 
 
 
 
1.3 Pathophysiology 
 
 
 
The pathophysiology of SFH is complex and not well understood. Several features have been 
proposed as potential triggers and the etiology is recognized as multi-factorial (figure 3). 
 
 
 
 
Figure 3: Pathophysiology of self-reported food hypersensitivity. Illustration by author. 
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1.3.1 Role of psychological and psychosocial factors 
 
 
 
The link between the GI tract and the central nervous system (CNS) is highly recognized, and GI 
disorders are often associated with psychological explanations. Countless of signaling network 
systems must cooperate in order to have an optimal functioning of gut physiology, and digestive 
tribulations in the GI tract are often linked to psychological disturbances, but no specific 
mechanisms have yet been elucidated. However, stress and psychological disorders, such as 
depression, anxiety and panic disorders, are generally assumed to worsen GI complaints (26, 27). 
The most common mental disorders among patients reporting SFH are depression and anxiety, 
whereas anxiety is predominant (28). In addition, reduced quality of life has been shown in these 
patients due to the unexplained symptoms that affect them in their daily lives and make them 
incapable of function optimally. However, a study from MAI team performed by Lind and 
colleagues at HUH, Bergen, indicated that physiological mechanisms could explain only 10 % of 
the variance in somatic symptoms, indicating that psychological aspects are not as relevant as 
previously assumed (29). Nevertheless, many patients reporting GI complaints experience that 
their bowel disorders are perceived as psychosomatic illnesses and these are often referred to 
psychological therapy in attempt to treat their symptoms. However, a meta-analysis concluded 
that the effect of carrying out psychological treatment in patients reporting GI complaints had 
questionable sustainability (24, 30). Also, the efficacy of providing drug therapies such as 
antidepressant medication for IBS patients has proven to be weak with indistinct evidences. 
However, anxiety and depression might activate complex networks in the CNS, resulting in 
cognitive-emotional sensitization and greater awareness of GI symptoms. This could be a major 
contributor in the development of abdominal hypersensitivity (24, 31, 32). Psychological and 
environmental factors typical of modern lifestyle, such as stress, health worries and anxiety are 
suggested as plausible causes of hypersensitivity reactions and have been associated with 
subjective health complaints. It is anticipated that psychosocial conditions are associated with 
functional GI diseases, but it is uncertain to what extent (15, 19, 29, 30). A study by Lind et al. in 
2005 revealed no significant difference in health worries between patients reporting subjective 
health complaints and controls. However, patients reported significantly more subjective health 
complaints than controls, and it is assumed the lack of managing stress and modern lifestyle 
greatly influences the daily life and contributes to a reduced quality of life in these patients (24). 
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1.3.2 Role of immunological factors 
 
 
 
It is highly recognized that the intestinal immune system closely interact with the enteric nervous 
system and previous studies from MAI team indicated that local, systemic and mucosal immune 
systems are activated in patients with SFH. Examples of immunologic biomarkers contributing 
to GI symptoms and inflammation are histamine, tryptase, calprotectin and ECP. These were 
measured in gut lavage fluid in a study by Arslan et al. from 2004, where they found that ECP 
and histamine concentrations were elevated in patients with SFH (18). Despite lack of specific 
food IgE antibodies, the study suggested that levels of local IgE located in the intestine might 
contribute to GI complaints (3). 
 
 
Immune activation is often prominent in IBS patients, and previous studies have suggested an 
important role of T and B cells in the pathophysiology of IBS. T and B cells are antigen-specific 
lymphocytes with distinct immunologic functions, upon activating result in an inflammatory 
immunologic response. In order to activate these cells they must interact with antigen presenting 
cells (APCs), whereas dendritic cells (DCs) are the most potent APCs. In an attempt to elucidate 
potential links between accumulations of DCs and SFH, Lied and colleagues performed a study 
in 2011 where they analyzed DC populations in patients with food hypersensitivity and in 
controls. No significant difference was observed between DC populations, however atopic 
participants produced significantly more IL-10, synthesized by monocyte-derived DCs (33). 
Also, levels of CD38, an immune cell-adherent glycoprotein, proved to be significantly 
correlated with levels of serum total IgE. 
 
 
Another study from MAI team at HUH, Bergen, indicated an involvement of B-cell activating 
factor (BAFF) in non-IgE mediated food hypersensitivity reactions. BAFF is an important 
regulator of B cell survival and a suggested link in food-related inflammation reactions. In this 
study, non-atopic patients had significantly higher levels of BAFF in serum and gut lavage fluid 
than atopic patients. In addition, no significant correlation was observed between BAFF and total 
IgE, which indicated that BAFF could be an important contributor in non-IgE-mediated allergic 
reactions to food (34). Recently, a study from Piuri et al. has supported the finding that BAFF is 
involved in non-IgE mediated allergic reactions. The second pathway of severe allergic reactions 
required a platelet activating factor (PAF), but not histamine, serotonin or leukotriens, and they 
found highly significant correlation between BAFF and PAF in non-atopic patients, from which 
they conclude that BAFF is probably one of the cornerstones of the alternative pathway of 
20  
allergy. Hence, the findings regarding increased number of “IgE-armed” mast cells (as 
mentioned before), BAFF and DCs support the notion of intestinal immune activation in these 
patients. 
 
 
 
 
1.3.3 Role of nutrition and intestinal fermentation 
 
 
 
IBS symptoms associated with GI dysfunction and food hypersensitivity may be triggered or 
aggravated by selected dietary components and treatment options often involve dietary 
intervention (35, 36). Many patients experience symptoms postprandial and therefore self- 
attribute their complaints to specific food items. Low-digestible carbohydrates (LDCs) are  
poorly tolerated by patients suffering from IBS and SFH, and consumption of LDCs is often 
reported to replicate symptoms (15, 37). LDCs represent poorly absorbable carbohydrates which 
are totally or partly fermented in colon, and the term comprises complex carbohydrates (i.e. fiber 
and starch) and a group of dietary short chained carbohydrates referred to as FODMAPs 
(fermentable oligosaccharides, disaccharides, monosaccharides and polyols) by Gibson and 
Shepherd. The group of FODMAPs includes fructose, lactose, fructo- and 
galactooligosaccharides (fructans, and galactans), and polyols (sugar alcohols: sorbitol, mannitol, 
xylitol and maltitol). These are poorly absorbable carbohydrates with the capability of water 
retention due to their osmotic activity, and therefore partially responsible for luminal distention 
in small intestine and diarrhea. From the small intestine, the LDCs enter colon and accumulation 
of carbohydrates in colon is problematic in terms of the colonic micro flora. Colonic anaerobic 
bacteria are capable of fermenting undigested carbohydrates entering colon, yielding methane, 
hydrogen gas and short chain fatty acids (SCFAs) as fermentation products (figure 4). Excessive 
bacteria fermentation causes a great deal of problems in hypersensitive patients reporting GI 
complaints, as a result of colon distention and bloating due to the excess amount of gas produced 
(15, 35). Thus, dietary LDCs responsible for intestinal water retention and gas production in 
colon should be avoided in attempt to treat bothersome symptoms such as diarrhea, bloating and 
flatulence in patients with SFH and IBS.  Therefore, consumption of insoluble fibers may worsen 
GI symptoms and a daily intake of large amounts of dietary fiber is not recommended in patients 
with IBS complaints, even though dietary fiber and starch in general is recommended to improve 
health status in the general population. However, in patients experiencing constipation as 
predominant, an increased intake of fiber is suggested to improve the condition (15, 35, 36). 
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Figure 4: 
 
 
 
 
Figure 4: LDCs digestion overview. Illustration by author, edited from 
www.healthassist.net and www.buzzle.com. 
 
 
 
 
Fructose malabsorption is suggested as an important link in understanding the pathophysiology 
of food hypersensitivity and food intolerance (38). Fructose is a monosaccharide which is 
absorbed via two mechanisms in small intestine. When present with glucose, fructose gets 
efficiently co-absorbed via glucose transporter 2 (GLUT2), whereas when existing in free form 
fructose is transported via GLUT5, a facultative fructose transporter of low capacity. Therefore, 
when free fructose is consumed in excessive amounts, the ability to absorb fructose varies, and 
malabsorption of fructose is common in hypersensitive patients. Thus, unabsorbed fructose 
remains in intestine lumen and reduces intestinal water flux. The colonic bacteria are capable of 
metabolizing the fructose load entering colon from the small intestine and generate large amount 
of gas. Thus, many patients experience symptom relief after fructose avoidance. However, 
fructose restriction in diet is challenging due to the high content in a variety of consumers food 
(35). Fructose exists in food as free fructose, sucrose or fructans, which is a fructose polymer. 
Free fructose is found in many fruits and also honey and syrups. Dietary sucrose is a 
disaccharide consisting of fructose and glucose, and is not acknowledged as a problem due to the 
efficient co-transport of the disaccharide via GLUT2. Fructans are found in wheat products and 
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therefore, many patients who encompass food hypersensitivity symptoms, sometimes experience 
symptom relief after trying a gluten free diet for a short period. 
 
Administration of omega 3 fatty acids has proven to benefit patients with GI symptoms and joint 
complaints, and the effect is suggested to be anti-inflammatory. In a pilot study performed by 
Gregersen and colleagues at HUH, Bergen, duodenal administration of seal oil was implemented 
in patients reporting food hypersensitivity. It was hypothesized that seal oil possessed the 
capability to block inflammatory prostaglandin E2 (PGE2) synthesis, and therefore inhibit 
inflammation symptoms. Significant symptom relief was accomplished, indicating a therapeutic 
effect of seal oil in these patients. However, oral administration had no effect, hence further 
investigations need to be carried out in this specific area (39). 
 
 
 
 
1.3.4 Role of post infectious changes 
 
 
 
Functional GI disorders may also be triggered by other factors, such as intestinal infections (i.e. 
parasites, bacteria) or frequently use of antibiotics. These factors might disturb the intestinal 
microbiota, leading to increased permeability, visceral hypersensitivity, low grade inflammation, 
immune activation among others, and thus initiate IBS manifestations in susceptible individuals 
(7, 40). A study at the University of Bergen confirmed a 80,5% prevalence of IBS among 
patients 12-30 months after the onset of a Giardia lamblia infection, proposing GI infections as 
important triggers of functional GI disorders (41). 
 
 
 
1.3.5 Role of enterochromaffin cells 
 
 
 
Serotonin is an important signaling substance and considered as one of the key neurotransmitters 
of the enteric nervous system prevalent in the gut. Generally, 95 % of the body's content of 
serotonin is believed to remain in the gut system. The substance is synthesized and secreted by 
the enterochromaffin (EC) cells, a subtype of enteroendocrine cells present in small intestine. 
Serotonin is released by these cells through luminal stimuli, and it is involved in a numerous gut 
functions, including GI motility, reflex coordination, secretion and sensation. Abnormal luminal 
contents of serotonin and alterations in serotonin metabolism may initiate GI symptoms and have 
been implicated in GI disorders including IBS and food hypersensitivity. As such, serotonin is 
suggested as an important biomarker in the pathophysiology of SFH (42, 43). However, a study 
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by Gregersen et al. from 2011 revealed no significant differences in levels of 5- 
hydroxytryptamine (5-TH, serotonin) in gut lavage fluid between patients with subjective food 
hypersensitivity and controls (44). 
 
 
 
 
1.3.6 Role of gut microbiota 
 
 
 
Recently, there has been an increased interest in the role of gut bacteria in functional GI 
disorders, and small intestine bacteria overgrowth (SIBO) has been suggested as a potential 
pathophysiological mechanism. SIBO indicates an abnormal escalation of the bacteria flora 
colonizing the small intestine, in which induce symptoms similar to IBS complaints. A high 
prevalence of SIBO in IBS patients is observed, and the condition is diagnosed by performing a 
lactulose breath test, in which increased amounts of gas in exhaled air indicates SIBO. Also, 
antibiotics and SIBO eradication has proven to improve symptoms in IBS patients (45, 46). 
 
In addition, recent investigations conclude that many symptoms associated with GI dysfunction 
can be explained due to dysbiosis of the gut micro flora. As mentioned, the bacteria colonizing 
the large intestine are important due to decomposition of indigestible food components entering 
the colon, and in maintaining a healthy bowel. An abnormal SCFA composition and excess 
amounts of gas is observed in many patients with GI complaints, indicating an unbalanced 
bacteria flora and disrupted fermentation process in these patients. These findings may in future 
be clinical applicable in elucidating important links in the pathophysiology of functional GI 
diseases (35, 47). 
 
The therapeutic effect of applying live microorganisms denoted as probiotics have been widely 
investigated and the appreciation of its health benefits in relation to IBS patients is growing. It is 
suggested that administration of multi-species probiotics may benefit the intestinal micro flora 
and reduce GI symptoms severity due to microbiota imbalance (36, 48). Additionally, fecal 
bacteriotherapy has been widely used as treatment for chronic GI infections, with successful 
results. Bacteriotherapy includes transplantation of the intestinal fecal flora from a healthy donor 
into a recipient, and optimistic results have also been observed in patients with IBS after 
administration (49). However, this kind of treatment needs further investigations and additional 
follow up-studies. 
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1.4 Diagnostic challenges 
 
 
 
Patients reporting functional GI complaints self-attributed to specific food items are at first 
referred by their physician to undergo allergologic examinations. These investigations include 
identifying the patients full medical history, skin prick tests and measurement of allergy 
parameters in serum, including specific IgE levels against susceptible food allergens (50). Also, 
elimination diets, open food challenges and double-blind placebo-controlled food challenges 
(DBPCFC) are often performed by dietitians to further investigate the patients’ different 
reactions to selected food. DBPCFC is highly recognized and is designated as the gold standard 
of identifying food allergy. Nevertheless, due to diffuse and subjective symptoms in patients 
reporting non-allergic food hypersensitivity, there are no validated diagnostic methods to verify 
the various complaints, thus patients are often diagnosed IBS when other organic diseases are 
excluded. Diagnosing IBS in patients with food hypersensitivity is based on addressing the 
Rome III criteria. However, this criteria does not reflect the patients overall complaints and 
health issues, such as fibromyalgi and fatigue, which often are dominant symptoms among SFH 
and IBS patients (51). As such, the patients do not obtain an exact diagnose and they remain 
uncertain about their condition, not knowing what to do in attempt to improve their health status. 
 
Scientists and physicians wish to come up with improved diagnostic methods for non-allergic 
food hypersensitivity, whereas intestinal allergen provocation test with endosonography and two- 
dimensional external abdominal ultrasound are examples of potential future techniques which 
could help physicians in obtaining more accurate diagnoses. During these tests, changing in 
intestinal wall thickness, peristaltic activity and luminal fluid could be monitored after 
administration of food allergen directly into the duodenum by a nasogastric sonde. However, 
these are preliminary research tools and must be validated before further use. Analyses of 
inflammatory immunologic markers, such as tryptase or ECP in serum, urine or gut lavage fluid, 
are also suggested as diagnostic tools for identifying patients reporting food hypersensitivity (11, 
52). 
 
Increased luminal levels of serotonin in intestine have, as previously mentioned, been proposed 
as an indicator of gut dysfunction in SFH patients. Biopsies and subsequent immunoassay 
determination are proposed methods for determining serotonin status in patients. Also, Gregersen 
et al. developed in 2007 a new method to measure serotonin level in gut lavage fluid in attempt 
to evaluate the serotonin status in SFH patients (42). However, the effect of serotonin and EC 
cells on the pathophysiology of GI disorders remains unclear. 
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The role of brain-gut axis dysregulation is not entirely confirmed, however the modularity effect 
of the CNS in gut motility and pain perception is highly recognized. In the last decades a 
remarkable development in brain imaging techniques has followed in an attempt to legitimize 
patients reporting undiagnosed functional GI symptoms. Positron emission tomography (PET), 
functional magnetic resonance imaging (fMRI) and also molecular examination of neurologic 
peptides are new procedures proposed to detect abnormalities in the brain-gut axis. These 
methods make it potentially possible to study the physiology of the brain and possibly 
understand the intrinsic role of CNS in modulating pain and motility in the gut (50, 53). 
 
 
 
 
1.5 Total IgE and atopic sensitization 
 
 
 
In a study at HUH, Bergen, from 2010, Lillestøl and colleagues discovered a significant 
correlation between elevated levels of serum total IgE and increased number of mast cells in 
duodenal mucosa in atopic patients, mainly as "IgE-armed” mast cells. Mast cell stimulation 
upon allergen exposure initiates degranulation and subsequent release of various mediators 
(figure 5). 
 
 
 
 
 
Figure 5: Mast cell degranulation. Illustration by 
www.brycelab.com. 
 
 
 
 
These mediators, including histamine and tryptase, were hypothesized by Barbara et al. to have 
the capability of altering the physiology of the enteric nervous system and lead to visceral 
hypersensitivity. In their study from 2004 they demonstrated a significant correlation between 
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abdominal pain and the presence of degranulated mast cells in IBS patients. Also, they detected 
an increased density of mast cells in proximity to nerves supplying the colonic mucosal (3, 53). 
In addition, mast cell release of other pro-inflammatory mediators can result in inflammation and 
cause a number of symptoms affecting the GI tract. It was thus suggested that “IgE-armed” mast 
cells might represent a pathological explanation due to subjective GI complaints in patients with 
functional GI disorders. 
 
Previous studies in children and adolescents with asthma revealed a relationship between higher 
levels of total serum IgE and impaired pulmonary function (reduced FEV1/FVC) (54-56). 
Haselkorn et al. examined the relationships of age and sex with allergic co-morbidities and total 
serum IgE levels with airflow in a cohort study, and observed a high rate of allergic rhinitis, 
atopic dermatitis, and sensitization to allergens (57). Higher levels of serum total IgE  were 
associated with lower pre-bronchodilator FEV1/FVC, independent of age, sex, and 
race/ethnicity, suggesting that total IgE may be a marker of asthma severity. However, such 
relationships between total IgE levels and GI complaints have not previously been investigated 
in patients with food hypersensitivity. 
 
Despite a low prevalence of classical specific IgE-mediated food allergy among patients who 
self-attribute GI complaints to food hypersensitivity, it is speculated that other atopic disorders 
(such as rhinitis, eczema and asthma) may play a role in the development of such complaints (18, 
28, 58). Patients with atopic background have higher level of specific IgE than non-atopic 
patients, and additional studies have elucidated that individuals with atopic diseases report more 
food hypersensitivity reactions than non-atopic (3, 59). This might represent a pathological link 
between functional GI disorders and increased levels of specific IgE antibodies in atopic patients 
(25). Elevated levels of specific IgE in blood serum indicate that the atopic patient is sensitized 
and more susceptible to evolve hypersensitive reactions to specific food items (60). Also, atopic 
patients with elevated specific IgE to pollen antigens can experience hypersensitization due to 
potential cross reactions with food antigens capable of conformation intended for IgE-interaction 
[9]. In a pilot study performed by Tobin and colleagues a strong correlation was observed 
between patients with atopic manifestations and the presence of IBS symptoms compatible with 
the Rome II Criteria (7). Consistent with these findings "atopic IBS" was recently proposed as a 
new subgroup of IBS, possibly with a distinct role of mast cells. 
 
Our aim in this extended study was to explore the relevance of total IgE and atopic sensitization 
in patients with IBS-like complaints self-attributed to food hypersensitivity. We know from 
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previous studies on functional GI disorders, that there are differences in gender and age when it 
comes to reporting GI complaints (20), and it has been documented that women on average 
report more bowel symptoms and IBS-like complaints than men. Also, GI complaints seem to 
tender with younger individuals, i.e. elderly appear to experience less GI complaints (20). 
Therefore, we also wanted to explore the impact of age and gender differences when it comes to 
the association between levels of total IgE or atopic sensitization and GI complaints. 
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2. AIMS OF STUDY 
 
 
 
Our main objective was to investigate the association between total IgE, atopic sensitization and 
GI symptoms. The specific aims of this proposal were as follows: 
 
 To investigate the association between serum total IgE levels and GI complaints. 
 
 
 To investigate the association between atopic sensitization and GI complaints. 
 
 
 To analyze whether there is a gender difference in the association between total IgE and 
GI complaints. 
 
 To analyze whether there is an age difference in the association between total IgE and GI 
complaints. 
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3. MATERIALS AND METHODS 
 
 
 
3.1 Patients 
 
 
 
A total of 161 patients with or without GI complaints referred by general practitioners to Section 
of Clinical Allergology, at the Department of Occupational Medicine, HUH for suspected allergy 
were indiscriminately recruited in our study from February 2011 to September 2013. The 
patients without GI complaints as primary cause of reference were a comparable group for the 
patients with GI symptoms. In addition, a group comprising 479 individuals, was provided from 
the European Community Respiratory Health Survey (ECRHS III) study to represent the general 
population. Our data were categorized as follows; 
 
A patient group divided in two subgroups according to primary cause of reference, i.e. patients 
who are referred to allergological examination with GI complaints as primary cause of reference 
(n=81) and patients who are referred to allergological examination with other allergic symptoms 
as primary cause of reference (n=80). 
 
A group sample representing the general population (n=479). 
 
 
All participants went through standard “allergy screening” and completed attached 
questionnaires. Patients with organic disease which could explain their abdominal symptoms, 
pregnant or lactating women were excluded. 
 
 
 
 
3.2 Allergological examination 
 
 
 
Allergological examination consisted of detailing patient’s history including levels of total and 
food-specific IgE. In the patient group, levels of total and specific IgE were analyzed by 
ImmunoCap-System (Phadia, Uppsala, Sweden). Inhalant and food allergens were measured 
using standard panels of Phadiatop (i.e. birch, timothy, Cladosporum herbarum, cat, dog, horse, 
mugwort, Dermatophagoides pteronyssinus and Dermatophagoides farinae) and fx5 food 
screening (i.e. cow's milk, egg white, wheat flour, soya, cod and peanuts). In the general 
population provided from ECRHS III, levels of total and specific IgE were analyzed using the 
Pharmacia CAP System (Pharmacia Diagnostics, Uppsala, Sweden). Specific IgE included 
Dermatophagoides pteronyssinus, cat and timothy. 
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Participants were divided into atopic and non-atopic subgroups, according to specific IgE levels 
in serum: Atopic individuals were defined by having increased levels of specific IgE antibodies 
to at least one allergen (> 0.35 kU/L). 
 
 
 
 
3.3 Questionnaires assessing GI complaints 
 
 
 
During the first session, all participants were asked to fill in two questionnaires to assess their GI 
complaints regarding symptoms and diagnosis of their complaints: 
 
The Questionnaire for Rome III criteria and functional GI complaints included the short form of 
the Rome III criteria and IBS Symptom Questionnaire, which both are widely used in diagnosing 
IBS and in quantification of functional GI disorders (61). The IBS symptom questionnaire (IBS- 
SQ) contains 6 symptoms which are rated on a scale of 0 - 10, where 0 = no symptoms and 10 = 
severe IBS. A total score of 15 or higher defined active symptoms for patients with IBS. In 
addition, the questionnaire also included four IBS criteria providing support for IBS diagnosis, 
four symptoms requiring further consideration, three criteria for functional dyspepsia, two 
symptoms supporting heartburn diagnosis and four additional questions to characterize all 
patients. 
 
IBS Symptom Severity Scale (IBS-SSS): The IBS-SSS contains five questions that are rated on a 
100-point visual analogue scale (VAS), in which are meant to give information about the 
severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal 
distension, dissatisfaction with bowel habits, and the GI complaints' interference with quality of 
life (62). All five components contribute to the score equally yielding a theoretical range of 0 – 
500, with a higher score indicating a worse condition. Previous studies have established that 
scores below 175 represent mild IBS symptoms, 175–300 represents moderate severity, and 
scores above 300 represent severe IBS (62). A decrease of 50 points on the IBS-SSS has been 
shown to correlate with improvement in clinical symptoms. 
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3.4 European Community Respiratory Health Survey 
 
 
 
The European Community Respiratory Health Survey (ECRHS) is a multicentre, international 
study initially set up in the early 1990’s to assess the prevalence of asthma and allergy in young 
to middle aged adults. Random population samples were selected within administrative 
boundaries in each study centre. At baseline, about 200,000 men and women answered a 
screening questionnaire, and approximately 26,000 persons participated in a clinical 
investigation. A follow-up study of the clinical cohort in 29 study centers, ECRHS II, was 
carried out in 1998-2002. The data collection of the third wave, the ECRHS III, has recently 
been performed. The ECRHS has been funded by the European Commission as part of the 
Quality of Life Programme, as well as by other sources. Over 500 papers have been published. 
 
From Norway, Bergen participates in the ECRHS. At baseline, a random population sample of 
4300 persons were invited to a screening questionnaire, and a subsample of 1200 responders 
were invited to a clinical examination of which 935 subjects took part. Six hundred subjects were 
re-investigated in 2000-01. In 2011, 12 475 persons have participated in the clinical follow-up, 
investigated with interview, lung function measurements, blood samples, skin prick tests and 
self-filled in questionnaires. The participants were asked to fill in two questionnaires about GI 
complaints (The Questionnaire for Rome III criteria and functional GI complaints and IBS 
Symptom Severity Scale). Total and specific IgE were analyzed as described above. 
 
 
 
 
3.5 Categorization of data and statistical analysis 
 
 
 
All data for patients were registered in FileMaker Pro 5.5 (Inc, California) by the same person. 
For participants from the ECRHS III study, the data were collected in IBM SPSS Data 
Collection Data Entry. 
 
Statistical analyses were performed by using IBM SPSS Statistics for Windows, Version 21, Inc. 
Chicago. We included two parameters to assess GI complaints severity, i.e. IBS-SSS and IBS- 
SQ. Pearson's correlation coefficient was used to assess the correlation between parameters 
including total IgE levels and severity of GI complaints, and the correlation analyzes were 
bivariate and two-tailed. Independent Student t-tests and one-way Anova were used for 
comparisons of means in different groups, followed by post hoc Scheffé pairwise comparisons. 
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Chi-square statistics were used for comparisons of proportions. Linear regression models were 
used to evaluate the association between total IgE levels and GI complaints (IBS-SSS), adjusting 
for atopic sensitization, gender, age and sample in multivariate regression models. A statistical 
value of p < 0.05 was considered statistically significant. 
 
 
 
 
3.6 Ethical Approval 
 
 
 
The clinical study was approved by the Regional Committee for Medical Research Ethics (REK 
2011/1118) and all patients and controls have given written informed consent. 
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4. RESULTS 
 
 
 
4.1 Demographic and clinical characteristics of the study populations 
 
 
 
Table 1 presents demographic data and characteristics among patients (referred for GI 
complaints or for other allergic complaints) and in the general population. 
 
 
 
 
Table 1: Demographic and clinical data in the study populations, a patient group and a general population 
sample. 
 
 Patient subgroups  
Patient group 
 
General 
population 
With GI 
complaints 
With other 
complaints 
N 
% Women 
% Men 
Age, mean years (range) 
IBS-Symptom Questionnaire 
(IBS-SQ) (mean) 
IBS-Symptom severity scale 
(IBS-SSS) (mean) 
IBS-SSS 
>300(severe) 
175-300 (moderate) 
75 - 175 (mild) 
<75 (no IBS) 
Allergy 
Total IgE (mean) 
Total IgE levels >120 kU/L 
Inhalant allergens positive 
Food allergens positive 
Atopic (%) 
81 
72.8 % (n=59) 
27.2 % (n=22) 
36.51 (17-75) 
 
23.74 
 
267.49 
 
33.3 % (n=27) 
42.0 % (n=34) 
16.0 % (n=13) 
3.7 % (n=3) 
 
279.79 
45.7 % (n=37) 
55.6 % (n= 45) 
37.0 % (n=30) 
56.8 % (n=46) 
80 
67.5 % (n=54) 
32.5 % (n=26) 
37.29 (15-71) 
 
13.96 
 
116.67 
 
7.50 % (n=6) 
22.50 % (n=18) 
21.25 % (n=17) 
42.5 % (n=34) 
 
336.22 
52.5 % (n=42) 
80 % (n=64) 
46.3 % (n=37) 
82.5 % (n=66) 
161 
70.2 % (n=113) 
29.8 % (n=48) 
36.90 (15-75) 
 
19.05 
 
193.07 
 
20.50 % (n=33) 
32.30 % (n=52) 
18.63 % (n=30) 
22.98 % (n=37) 
 
312.94 
49.07 % (n=79) 
67.7 % (n=109)* 
41.61 % (n=67)** 
69.57 % (n=112) 
478 
44.7 % (n=214) 
55.3 % (n=264) 
52.51 (40-64) 
 
5.92 
 
70.77 
 
1.88 % (n=9) 
5.65 % (n=27) 
25.70 % (n=123) 
62.34 % (n=298) 
 
75.5 
12.97 % (n=62) 
21.5 % (n=103)*** 
 
21.5% (n=103) 
 
* % with positive specific IgE (< 0.35 kU/L) to at least one inhalant allergen (Standard panels of inhalant, 
Phadiatop, ImmunoCAP, Phadia AB, Uppsala, Sweden). 
** % with positive specific IgE (< 0.35 kU/L) to at least one food allergen (Standard panels of food (fx5) 
allergens (ImmunoCAP, Phadia AB, Uppsala, Sweden). 
*** % with positive specific IgE (< 0.35 kU/L ) to one of the following inhalant allergens: grass, cat or 
Dermatophagoides pteronyssinus. 
 
 
 
The presence of atopic sensitization and elevated levels of specific IgE and total IgE were higher 
in both patient subgroups compared to the general population. Timothy and birch were the most 
common inhalant allergens in patients with GI complaints, whereas sensitization to timothy, 
Dermatophagoides pteronyssinus, birch and dog were most common in patients with other 
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complaints. With regard to food allergens, hazelnut, wheat and peanut were the most common 
allergens in patient group (tables are presented in Appendix 5, table 1 and 2 ). 
 
 
Both patient subgroups had more GI complaints than the general population (table 2). Among 
patients, abdominal pain was the most common GI symptom, affecting 123 patients (76.4 %), 
followed by changes in frequency of stool (59 %) and bloating (61.5 %), which is consistent with 
IBS triad. In the general population, bloating and diarrhea were the most common symptoms 
(table 2). 
 
 
 
 
Table 2: Specific GI complaints in the study populations 
 
 Patient group  
Patient group 
 
General 
populatio
n 
With GI 
complaints 
With other 
complaints 
% GI complaints 
- % with abdominal pain or 
discomfort last 3 months 
- % change in frequency of 
stool 
- % with bloating and/or 
abdominal distention 
- % with defecation at night 
- % with diarrhea 
predominant 
- % with constipation 
predominant 
- % med functional dyspepsia 
- % with heartburn 
 
96.3 % (n=78) 
 
79.0 % (n=64) 
 
76.5 % (n=62) 
 
19.8 % (n=16) 
61.7 % (n=50) 
 
27.2 % (n=22) 
 
65.4 % (n=53) 
49.4 % (n=40) 
 
56.3 % (n=45) 
 
38.8 % (n=31) 
 
46.3 % (n=37) 
 
8.8 % (n=7) 
40.0 % (n=32) 
 
16.3 % (n=13) 
 
23.8 % (n=19) 
31.3 % (n=25) 
 
76.4 % (n=123) 
 
59.0 % (n=95) 
 
61.5 % (n=99) 
 
14.3 % (n=23) 
50.9 % (n=82) 
 
21.7 % (n=35) 
 
44.7 % (n=72) 
40.4 % (n=65) 
 
29.0 % (n=139) 
 
22.3 % (n=107) 
 
41.3% (n=198) 
 
2.7 % (n=13) 
38.6 % (n=185) 
 
15.4 % (n=74) 
 
15.9 % (n=76) 
28.8 % (n=138) 
 
 
 
 
 
Figure 6 presents an illustration of IBS-SSS scores (A) and IBS-SQ scores (B) in the different 
groups. Both patient subgroups reported more GI complaints than the general population (p < 
.001), and this was the same for both scoring systems of GI complaints. Patients with other 
complaints reported less abdominal complaints than patients with GI complaints (p < .001). 
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Figure 6: (A) IBS-SSS scores, including IBS grading score, and (B) IBS-SQ scores between 
different groups, giving us the medians, interquartiles and 95 % confidence intervals. 
According to table 1 and figure 7, total IgE levels were higher in patient subgroups compared to 
the general population (patients with other complaints: mean = 336.22, patient group with GI 
complaints: mean = 279.78 and general population: mean = 75.7) (p < .001). Within the patient 
subgroups, patients with other allergic symptoms as cause of reference had higher levels of total 
IgE compared to patients referred for GI complaints, however this difference was not 
significant (p = .563). 
Figure 7: Means of total IgE in the different groups. 
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The distribution of atopic sensitization did significantly differ between groups (p < .001), 
whereas the patient subgroup with other complaints had also the highest prevalence of atopic 
sensitized (figure 8). 
Figure 8: Prevalence of atopic sensitization in the study 
populations. 
4.2 Bivariate relationship between GI complaints and total IgE 
We conducted correlation analyzes for the patient group and general population in order to test 
whether levels of total IgE correlated with GI complaints, i.e. IBS-SSS and IBS-SQ. 
Patient group 
No significant correlation was observed between total IgE and IBS-SSS (r = .072, p = .379) or 
total IgE and IBS-SQ (r = .084, p = .311) (figure 9, A and B). Analyzing each patient subgroup 
separately revealed no significant correlations (Appendix 6, figure I and II). 
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Figure 9: Correlation analyzes in patient group (n = 161) between A: total  
IgE and IBS-SSS (r = .072, p = .379) and B: total IgE and IBS-SQ (r = .084, p 
= .311). 
General population 
In the general population group, a significant correlation was discovered between total IgE and 
IBS-SSS (r = .102, p = .029), but not between total IgE and IBS-SQ (r = .059, p = .201) (figure 
10, A and B). 
Figure 10: Correlation analyzes in general population between A: total IgE 
and IBS-SSS (r = .102, p = .029) and B: total IgE and IBS-SQ (r = .059, p = 
.201). 
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4.3 Bivariate relationship between GI complaints and atopic sensitization 
Patient group 
We conducted an independent t-test in the patient group in order to compare GI complaints (IBS- 
SSS scores and IBS-SQ scores) in atopic and non-atopic persons (atopic sensitization was 
defined as having elevated specific IgE ( > 0.35kU/L) to standard panels of inhalant allergens 
(phadiatop) and/or standard panels of food allergens (fx5) in the patient group). 
Figure 11: Mean IBS-SSS scores (A) and mean IBS-SQ scores (B) between non-atopic and 
atopic in patient group. 
We observed a significant difference in IBS-SSS scores (p = .011) and IBS-SQ scores (p = .036) 
between groups (figure 11, A and B). The non-atopic persons reported on average significantly 
more GI complaints (mean IBS-SSS = 232.77, mean IBS-SQ = 22.11) than atopic persons (mean 
IBS-SSS = 175.30, mean IBS-SQ = 17.77), and this was consistent for both scoring systems for 
GI complaints. Independent t-tests comparing means in IBS-SSS and IBS-SQ between atopic 
and non-atopic in patient subgroups are presented in Appendix 7, figure III and IV. 
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General population 
A similar tendency was observed in the general population sample (figure 12, A and B), and in 
this study sample atopic sensitization was defined as having elevated levels ( > 0.35 kUa ⁄ L) of 
specific IgE to at least one of the following allergens: Dermatophagoides pteronyssinus, cat or 
grass. On average, non-atopic persons reported more GI complaints (mean IBS-SSS = 71.71) 
than atopic persons (mean IBS-SSS = 64.48). However, this difference was not statistically 
significant (p = .362). The same results was observed when comparing IBS-SQ means, whereas 
non-atopic reported more GI complaints (mean IBS-SQ = 6.07) than atopic (mean IBS-SQ = 
5.18), but the difference was not significant (p = .268). 
Figure 12: Mean IBS-SSS score (A) and mean IBS-SQ score (B) between non-atopic and atopic 
in general population. 
4.4 Multiple regression analyzes of predictors of GI complaints 
We conducted multiple linear regression analyzes in order to investigate the association between 
total IgE, atopic sensitization, sex, age and GI complaints (IBS-SSS) in the patient group and in 
the general population. 
In the following statistical analyzes we have only implemented IBS-SSS scores as a marker of 
GI complaints, because IBS-SSS and IBS-SQ were highly correlated in both patient group (r = 
.798, p < .001) and in the general population (r = .664, p < .001), indicating similar findings in 
relation to atopic sensitization and total IgE as shown below (regression analyzes including IBS- 
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SQ are presented in Appendix 8, table III - V). The regression models are considered as robust, 
given that the coefficients do not change front signs and have no dramatically different values in 
the second model with statistical adjustments. All changes in ∆-values in the regression and 
interaction analyzes are calculated as new value minus old value, and levels of confidence 
intervals (CI) are set at 95% for all unstandardized regression coefficients. 
 
 
 
 
Patient group 
 
 
Table 3: The association between GI complaints (IBS-SSS) and total IgE, atopic sensitization, sex and 
age in patient group, analyzed with multiple regression analysis. Model 1 is unadjusted and model 2 is 
adjusted for atopic sensitization, sex and age. 
 
 IBS-SSS 
B 95 % CI SE b p-value 
Model 1 (unadjusted) 
 
Total IgE 
 
 
.019 
 
 
(-.023, .061) 
 
 
.021 
 
 
.379 
Model 2  
 
.036 
 
 
(-.007, .078) 
 
 
.021 
 
 
.097 
 
Total IgE 
 
Atopic sensitization* 
 
-77.216 
 
(-124.292, -30.140) 
 
23.818 
 
.001 
 
Sex 
 
-1.048 
 
(- 45.676, 43.580) 
 
22.580 
 
.963 
 
Age 
 
-1.338 
 
(-2.717, .042) 
 
.698 
 
.057 
The following symbols represent: b = unstandardized beta coefficient and SE = standard error.  
Note: R
2 
= .005 for model 1, ∆R
2 
= .080 for model 2 (p = .012). 
*Atopic sensitization was defined as having elevated specific IgE (> 0.35kU/L) to standard panels of 
inhalant allergens (phadiatop) and/or standard panels of food allergens (fx5). 
 
 
 
 
Total IgE was positively associated with GI complaints, however the association was not 
significant (b = .019, p = .379) (table 3, model 1). When adjusting for sex, age and atopic 
sensitization (model 2), the association between total IgE and GI complaints was borderline 
significant (b = .036, p = .097). Measured by the p-values, atopic sensitization was the largest 
contributor, which was significantly associated with less GI complaints (b = -77.216, p = .001). 
Total IgE accounted for 0.5 % of the total variance in GI complaints in the unadjusted analysis of 
the patient group. When sex, age and atopic sensitization were included in the multiple 
regression model, the amount of explained variance increased to 8.0 % (p = .012). Total IgE and 
atopic sensitization could together explain 6.2 % of total variance in GI complaints in a multiple 
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regression model only adjusting for levels of total IgE and atopic sensitization (∆R2 = .062, p = 
 
.009). 
 
 
 
 
 
General population 
 
 
Table 4: The association between GI complaints (IBS-SSS) and total IgE, atopic sensitization, sex and 
age in the general population, analyzed with multiple regression analysis. Model 1 is unadjusted and 
model 2 is adjusted for atopic sensitization, sex and age. 
 
 IBS-SSS 
b 95 % CI SE b p-value 
Model 1 (unadjusted) 
 
Total IgE 
 
 
.028 
 
 
(.003, .054) 
 
 
.013 
 
 
.029 
Model 2  
 
.038 
 
 
(.012, .064) 
 
 
.013 
 
 
.005 
 
Total IgE 
 
Atopic sensitization* 
 
-14.394 
 
(-30.670, 1.883) 
 
8.282 
 
.083 
 
Sex 
 
-8.980 
 
(-21.939, 3.979) 
 
6.594 
 
.174 
 
Age 
 
-.360 
 
(-1.327, .607) 
 
.492 
 
.464 
The following symbols represent: b = unstandardized beta coefficient and SE = standard error.  
Note: R
2 
= .010 for model 1, ∆R
2 
= .014 for model 2 (p =.027). 
*Atopic sensitization was defined as having elevated specific IgE (> 0.35kU/L) to one of the following 
allergens: grass, cat or Dermatophagoides pteronyssinus. 
 
 
 
 
In the general population sample, total IgE was significantly associated with IBS-SSS in both the 
unadjusted analysis and the adjusted analysis (table 4). The size of the estimate was similar as to 
that in the patient group (b = .038, p = .005 and b = .036, p = .097, respectively). A negative 
association with atopic sensitization was detected in the general population (b = -14.394, p = 
.083) (table 4, model 2), as also seen in the patient group. Total IgE accounted for 1.0 % of the 
total variance in GI complaints in unadjusted analysis of the general population sample. Total 
IgE and atopic sensitization could together explain 1.9 % of total variance in GI complaints in a 
multiple regression model only adjusting for levels of total IgE and atopic sensitization (∆R2= 
.019, p = .014). 
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Total study population 
 
 
Because similar associations were detected among patients and in the general population, these 
groups were merged into one group in order to obtain a larger sample. Notable modifications in 
the adjusted regression model were definition of atopic sensitization and the introduction of a 
group sample variable. 
 
 
 
 
Table 5: The association between GI complaints (IBS-SSS) and total IgE, atopic sensitization, sex, age 
and sample in total study population (n = 639), analyzed with multiple regression analysis. Model 1 is 
unadjusted and model 2 is adjusted for atopic sensitization, sex, age and sample. 
 
 IBS-SSS 
b 95% CI SE b p-value 
Model 1 
 
Total IgE 
 
 
.065 
 
 
(.041, .088) 
 
 
.012 
 
 
<.001 
Model 2  
 
.037 
 
 
(.015, .059) 
 
 
.011 
 
 
.001 
 
Total IgE 
 
Atopic sensitization* 
 
-33.855 
 
(-50.963, -16.748) 
 
8.711 
 
<.001 
 
Sex 
 
-7.471 
 
(-21.810, 6.869) 
 
7.301 
 
.307 
 
Age 
 
-.788 
 
(-1.530, -.046) 
 
.378 
 
.037 
 
Patient group or general 
 
115.888 
 
(94.601, 137.175) 
 
10.839 
 
<.001 
population group 
The following symbols represent: b = unstandardized beta coefficient and SE = standard error.  
Note: R
2 
= .046 for model 1, ∆R
2 
= .251 for model 2 (p < .001). 
*Atopic sensitization was defined as having elevated specific IgE (> 0.35kU/L) to standard panels of 
inhalant allergens (phadiatop) in patient group and as having elevated specific IgE (> 0.35kU/L) to grass, 
cat or Dermatophagoides pteronyssinus in general population. 
 
 
 
 
Due to the lack of data on specific IgE to food allergens and selected inhalant allergens in the 
general population, we excluded data on food allergens in the patient group, in order to have 
approximately the same definition of atopic sensitization in the combined group. We also 
adjusted for group sample in this model, to investigate if whether this variable was a significant 
predictor of GI complaints. 
 
GI complaints were found to be significantly associated with total IgE (b = .037, p = .001), and 
inversely significantly associated with atopic sensitization (b = -33.855, p < .001) when adjusting 
for group sample status, in addition to sex and age (table 5). The estimate of the association 
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between GI complaints and total IgE was similar to the estimates previously found in the patient 
group and general population when analyzed separately. 
 
According to the multiple regression analysis (table 5), the group sample variable was 
significantly associated with GI complaints, whereas patients on average reported more GI 
complaints than the general population (b = 115.888, p < .001). We therefore performed a 
regression analysis in order to test if there was a significant interaction effect of IgE and group 
sample on GI complaints. No significant interaction was found (p = .395), implying that the 
association between total IgE and GI complaints was not significantly different in the two 
samples (patient group and general population). 
 
 
 
 
4.5 Stratified sampling and analysis of interaction by gender and atopic status 
 
 
 
Stratified sampling according to gender was performed in order to investigate whether the 
associations of GI complaints with total IgE levels differed between men and women. 
 
 
 
 
Table 6: The association between GI complaints (IBS-SSS) and total IgE in men (n = 296) and women (n = 
304), analyzed with multiple regression analysis and adjusted for *atopic sensitization, age and sample. 
 
 
 
Subgroup 
Direct effect of total IgE on IBS-SSS 
 
b (95% CI) 
 
 
p-value 
Men 
 
Women 
.026  (-.003, .056) 
 
.045  (.013, .078) 
.079 
 
.006 
The following symbol represent: b = unstandardized beta coefficient. 
*Atopic sensitization was defined as having elevated specific IgE (> 0.35kU/L) to standard panels of 
inhalant allergens (phadiatop) among patients and as having elevated specific IgE (> 0.35kU/L) to grass, 
cat or Dermatophagoides pteronyssinus in the general population. 
 
 
 
Similarly, stratified sampling were computed according to atopic status among the included 
participants, with the intention to investigate if the association between total IgE and GI 
complaints differed between atopic and non-atopic individuals. 
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Table 7: The association between GI complaints (IBS-SSS) and total IgE in atopic individuals (n = 202) 
and non-atopic individuals (n = 398), analyzed with multiple regression and adjusted for sex, age and 
sample. 
 
 
 
Subgroup 
Direct effect of total IgE level on IBS-SSS 
 
b (95% CI) 
 
 
p-value 
Atopic 
Non-atopic 
.040  (.014, .065) 
 
.044  (-.029, .118) 
.003 
 
.236 
The following symbol represent: b = unstandardized beta coefficient 
 
 
 
According to table 6 and 7, we see approximately the same consistent direct effect of total IgE 
on GI complaints in all stratified samplings. We performed a regression analysis to test if there 
was a significant interaction effect of IgE and gender on GI complaints in addition to the direct 
effect of IgE controlled for the other explanatory variables used previously. Women had more GI 
complaints than men, but the interaction effect was not significant (p = .721), indicating that the 
associations between total IgE and GI complaints (IBS-SSS) were not different in men and 
women. Correspondingly, a regression analysis was performed in order to examine if there was a 
significant interaction effect of IgE and atopic sensitization on GI complaints. No significant 
interaction effect was found (p = .556), suggesting that the effect of IgE on GI complaints was 
evenly distributed between atopic and non-atopic individuals. 
 
Furthermore, we performed stratified sampling according to age. We divided the total study 
population into two age subgroups, i.e. participants aged under 50 (range: 15 - 49) and 
participants aged over 50 (range: 50 - 75). Multiple regression analyzes performed in these 
subgroups are presented in the following table (table 8). 
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Table 8: The association between GI complaints (IBS-SSS) and total IgE in participants aged under 50 (n 
= 286) and over 50 (n = 314), analyzed with multiple regression and adjusted for *atopic sensitization, 
sex and sample.  
 
 
 
Subgroup 
Direct effect of total IgE level on IBS- 
SSS 
 
b (95% CI) 
 
 
p-value 
 
 
Individuals aged under 50 
Individuals aged over 50 
 
 
.050  (.018, .082) 
 
.020  (-.010, .049) 
 
 
.002 
 
.191 
The following symbol represent: b = unstandardized beta coefficient 
*Atopic sensitization was defined as having elevated specific IgE (> 0.35kU/L) to standard panels of 
inhalant allergens (phadiatop) in patients and as having elevated specific IgE (> 0.35kU/L) to grass, cat or 
Dermatophagoides pteronyssinus among the general population. 
 
 
 
 
We performed a regression analysis to test whether there was a significant interaction effect of 
IgE and age on GI complaints. We observed that the younger participants had more GI 
complaints than the elder, however the difference was not significant (p = .241), indicating that 
the effect of total IgE on GI complaints was evenly distributed between respondents with 
different age. 
 
Thus, the association between total IgE and GI complaints appeared to be consistent in all 
subgroups, with no significant differences according to gender, atopic status, or age. 
 
In addition, we performed analogous regression analyzes to test if there was a significant 
interaction effect of atopic sensitization and gender, or atopic sensitization and age, on GI 
complaints. The interaction effect of atopic sensitization and gender was not significant (p = 
.526). Neither did we find any significant interaction effect of atopic sensitization and age on GI 
complaints (p = .162). Hence, we verified that the negative association between atopic 
sensitization and GI complaints was not significantly influenced by gender or age. 
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DISCUSSION 
5.1 Summary 
To our knowledge, this is the first study where the association between total IgE levels, atopic 
sensitization and food-related GI complaints (symptoms of IBS) has been investigated. Our main 
aim was to investigate the relationship between total IgE, atopic sensitization and GI complaints. 
IBS-SSS and IBS-SQ were thus used as diagnostic tools to address the severity of GI complaints 
in the current study. We hypothesized that total IgE and atopic sensitization would be positively 
associated with GI complaints, in accordance with previous studies revealing increased number 
of "IgE-armed" mast cells in duodenal mucosa of patients with food hypersensitivity (3). Our 
results indicated that both total IgE levels and atopic sensitization were higher in patients and 
there was a positive, but non- significant, association between GI symptoms and total IgE in 
patients, whereas this association was significant in the general population. Also, we found that 
there was a negative relationship between GI symptoms and atopic sensitization, which was 
significant in the patient group, indicating no vital role of allergic sensitization in the actual 
development of unexplained SFH. When analyzing men and women separately, we found 
similar consistent associations between total IgE and GI complaints. This was also the same 
when we analyzed the participants according age, whereas we separated the participants in two 
age groups. We detected the same tendencies in the patient group and in the general population, 
and also among atopic and non-atopic, thus the association of GI complaints with higher IgE 
levels was a consistent finding. However, total IgE and atopic sensitization could together 
explain a relatively small proportion of the total variance in GI complaints in both study 
populations (6.2 % and 1.9 %, respectively). 
5.2 Results from study 
In this study we found that abdominal pain and discomfort were the most prominent GI 
complaints among patients (76.4 %) followed by bloating (61.5 %) and change in frequency of 
stool (59.0 %), whereas bloating was most common in the general population, affecting 41.3 %. 
These observations are consistent with previous findings in patients with SFH, whereas 
abdominal pain and discomfort are the predominant GI symptoms (1, 18, 33). Interestingly, we 
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also observed a high prevalence of GI complaints in our patient subgroup referred to 
allergological examination with other allergic symptoms as primary cause of reference. Both 
patient subgroups had higher prevalence of atopic sensitization compared to the general 
population. However, total IgE levels and prevelance of atopic sensitization were higher in the 
patient subgroup with other complaints as primary cause of reference, than in the patient 
subgroup with GI complaints. This also suggests that even though these two patient subgroups 
have different primary causes for referring to Section of Clinical Allergology, patients with other 
allergic symptoms as predominant also have symptoms of IBS in addition to higher levels of 
total IgE and atopic sensitization. 
Timothy, birch and dog were the most common inhalant allergens in patient group, whereas 
hazelnut, wheat and peanut were the most common food allergens. This corresponds with 
previous findings in patients reporting food hypersensitivity (3, 18). Although we demonstrated 
that atopic sensitization was negatively associated with GI complaints, the association between 
levels of specific IgE to the selected food allergens and GI complaints are interesting topics for 
further research. 
The various GI complaints reported among the included participants in this study were 
compatible with IBS symptoms, and we found that 71.4 % of the patients had IBS, whereas 
20.5 % had symptoms of severe IBS. In the selected patient subgroups, 91.4 % had IBS in the 
group comprising patients with GI complaints as primary cause of reference. Surprisingly, over 
half of the patients comprising the second patient subgroup also had symptoms of IBS in 
addition to other allergic symptoms. It is also interesting that this group consisted of patients 
with the highest levels of total IgE and the highest prevalence of atopic individuals, indicating a 
potential link between these variables and GI symptoms. The two patient subgroups were 
initially categorized based on referral reason and to demographically describe the different 
patients, but considering the analyzes of relationship between total IgE or atopic sensitization 
and GI complaints, this division of patients was not of interest, and we therefore merged the two 
subgroups in one patient group. In the general population, one third had IBS, however most of 
these individuals had a mild form of IBS, whereas only 1.88 % suffered from severe IBS, 
indicating that GI complaints did not have any major impact in these participants daily life. In 
the patient group 22.98% had no symptoms of IBS, while 62.34 % had no symptoms of IBS in 
the general population. 
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The patient group was considered as an atopic group with a high prevalence of atopic 
sensitization, and levels of total IgE were significantly higher in patients compared to the general 
population group. There was no significant correlation between total IgE and GI complaints 
specified as IBS-SSS and IBS-SQ in the patient group. However, in the general population group 
there was a significant correlation between total IgE and IBS-SSS, but not between total IgE and 
IBS-SQ. This difference observed in significant values was most likely due to the different group 
sizes, where the general population group is a much larger sample. 
 
A significant difference was observed between atopic and non-atopic patients according to IBS- 
SSS, where non-atopic on average reported more GI complaints than atopic in patient group. The 
same tendency was seen in general population, but the means were not significantly different 
between atopic and-non atopic individuals. The different definitions of atopic sensitization in the 
two groups were likely to be the cause of difference in significant values. In patient group, the 
only variable accounting for significant effect in multiple regression analysis was atopic 
sensitization, defined as elevated levels of specific IgE to at least one allergen. Total IgE was not 
significantly associated with GI complaints in this group. Same indications were observed in 
general population, where total IgE was significantly associated with GI complaints. The effect 
of atopic sensitization was not significant in this group, however this might be because atopic 
sensitization was defined different in this group. In the current study, total IgE and atopic 
sensitization could together explain 6.2 % and 1.9% of total variance in GI complaints in the 
patient group and general population respectively. 
 
We found the same tendencies in both the patient group and the general population, where total 
IgE significantly correlated with GI complaints in the general population sample. Also, similar 
results were observed according to the association between GI complaints and atopic 
sensitization, in which atopy appeared to have an inverse effect on GI symptoms in both groups 
as non-atopic persons have more GI complaints. We therefore combined the patient group and 
the general population in one merged group, in order to observe the variable's effects in a larger 
sample. Every explanatory variable, with the exception of sex, was significantly associated with 
GI complaints in the combined group comprising all participants, whereas atopic sensitization 
had the greatest effect. This observation in a total study population supported our previous 
findings. 
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According to our stratified and interaction analyzes, there were not observed any significant 
interaction effects of gender or age when it came to the association between total IgE or atopic 
sensitization and GI complaints respectively. 
 
GI disorders are very common in the western civilization, and patients reporting GI complaints 
self-attributed to food items comprise a selected group. The GI symptoms reported by these 
patients after consumption of food are often compatible with IBS, and according to the Rome 
criteria many of these patients are diagnosed IBS (1, 18). The pathophysiology of IBS is yet not 
well understood, however several mechanisms are suggested. It is observed that consumption of 
low digestible carbohydrates, such as FODMAPs, triggers GI complaints and may worsen the 
situation. Subsequent bacterial fermentation in the colon could cause excess amounts of 
intestinal gas and distention, in which is a major contributor of abdominal pain and discomfort 
(15, 37, 38, 63). Also, the role of the gut microbiota is recognized as vital, whereas bacterial 
dysbiosis or changes in the intestinal micro flora is known to cause GI complaints (21, 47, 64). 
Often, patients reporting severe GI illnesses are recognized as psychosomatic, and therefore 
many are referred to a psychologist in attempt to offer these patients treatment. However, a study 
from MAI team demonstrated that psychological factors were not major predictors of GI 
symptoms in patients reporting food hypersensitivity (29). 
 
 
 
 
5.3 Limitation of study and methodological issues 
 
 
 
5.3.1 Participants and design of study 
 
 
 
The two groups included in this study were somewhat different, whereas the general population 
was a much larger sample. The effect of this was two-sided, whereas the large group sample of 
the general population contributed to strengthen our results, however it also made it somewhat 
difficult to compare the two groups in an overall perspective. Regarding the general population 
sample, it is important to have in mind that the participants in the general population were not 
defined as healthy controls, but as representatives of general population. The different age ranges 
were also set to be different among the two groups, whereas the general population consisted of 
elder people than the patient group. Because of missing data of specific IgE to food allergens and 
certain inhalant allergens in the general population, the definition of atopic sensitization was to 
some extent different in the two groups. 
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5.3.2 Use of IBS-SSS and IBS-SQ in a general population 
 
 
 
The IBS-SSS and IBS-SQ questionnaires are developed for use in patient populations with GI 
complaints. In a general population, subjects with no such complaints often did not answer the 
questions. Missing information was thus re-coded as “no”. The misclassification introduced by 
this is likely to have attenuated associations. 
 
 
 
 
5.3.3 Food allergens and GI complaints 
 
 
 
In the current study, we did not investigate the association between the severity of GI complaints 
and positive specific IgE levels to specific food allergens, such as cow`s milk, milk protein, 
gluten and wheat in the selected groups. This should be followed up in additional studies on the 
pathophysiology of food hypersensitivity and IBS. 
 
 
 
 
5.3.4 Data collection 
 
 
 
Due to the large timeframe, comprising over 2 years, of this study, there have been several 
different allergologic physicians responsible for the data collection in the patient group. This 
may contribute to random errors on the collected patient material, especially when it comes to 
the primary cause of reference in the two patient subgroups. 
 
 
 
 
5.4 Reflections on findings 
 
 
 
The prevalence of atopic diseases among patients with GI disorders, including IBS, is highly 
recognized (3, 7, 14, 65, 66), and vice versa, GI symptoms are frequently reported in allergic 
individuals, thus potential links between atopic disorders and GI diseases are proposed (67). 
Mast cells have also been suggested to play a key role in the development of GI disorders, 
including inflammatory bowel disease and IBS (53, 68), and O'Sullivan et al. found in a study 
from 2000 a significantly increased number of colonic mast cells in IBS patients, compared to 
controls (69). Interestingly, they found in a study from MAI team that the number of duodenal 
IgE-positive cells were significantly higher in atopic patients than in non-atopic, in which 
51  
appeared to be "IgE-armed" mast cells (3). The atopic patients also had increased intestinal 
permeability when compared with non-atopic patients. These observations of histological 
changes in the GI region of patients with allergic diseases are consistent with some previous 
investigations (4-6, 70). Thus, according to various studies, "atopic IBS" was recently proposed 
as a new subgroup of IBS, with a distinct role of activated mast cells (3, 7), and identifying atopy 
in patients with IBS symptoms was suggested as an important link in elucidating the 
pathophysiology of IBS. The following study demonstrated that levels of total IgE were 
significantly associated with GI complaints in a general population, suggesting a pathological 
link between food-related IBS-symptoms and increased levels of total IgE. Atopic sensitization 
appeared to have no vital influence on GI symptoms in both group samples, in contrast to 
previous studies linking atopic diseases and IBS. In fact, our results indicated a significant 
negative association between atopic sensitization and GI complaints among patients, contrary to 
our initiated hypothesis. Together, total IgE and atopic sensitization could explain only a small 
proportion of GI complaints, i.e. 6.2 % and 1.9 % in patient group and general population, 
respectively. These observations support that specific IgE-mediated processes appear to have 
little impact on IBS-like complaints, and that atopic sensitization and/or allergy play a small role 
in the actual development of food-related GI complaints. Although patients with IBS previously 
have been shown to have an increased number of mast cells located in the gut, it is not 
anticipated that classical IgE-mediated sensitization is the cause of GI symptoms (53, 69, 71). 
Mast cells encompass membrane IgE receptors, capable of attaching circulating IgE antibodies, 
and in accordance to the documentation of a significant correlation between IgE-armed mast 
cells and serum total IgE by Lillestøl et al., it is conceivable that the increased number of 
mucosal armed mast cells induce intestinal hypersensitive to a variety of mechanical stimuli, 
including bloating, distension and water retention (3). Visceral hypersensitivity is commonly 
found in patients with IBS, and several studies indicate abdominal symptom relief after mast cell 
stabilizer administration (72). Whether the cause of the increased number of IgE-cased mast cells 
in intestinal mucosa is in concordance with increased levels of total IgE in serum is yet  
uncertain, and we do not know if this discovery revealing total IgE as a significant predictor of 
GI complaints in a general population is yet of clinical significance. However we do believe that 
the term "atopic bowel" may be of particularly interest in patients with high total IgE in serum. 
 
Conversely, the actual role of total IgE levels in serum in the development of food-related GI 
complaints and IBS must be investigated further by mechanistic and epidemiological studies in 
order to clarify whether high total IgE a primary or secondary cause of IBS. Also, conditions 
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which contributes to elevated levels of total IgE are interesting topics for further research. 
Parasitic infections in human are persuasive stimulus for IgE production, and helminth parasites 
are considered as one of the most potent invasive infections leading to synthesis of IgE 
antibodies and elevated levels of serum total IgE (73). Helminths represent one of the most 
prevalent form if parasitic infections in human, often resident in the GI tract, whereas food items 
and poorly washed vegetables are one of the major sources (74). Levels of serum total IgE have 
also been associated with asthma and reduced pulmonary function. Haselkorn et al. demonstrated 
in a study from 2010 a significant association between high levels of serum total IgE and  
reduced lung capacity, indicating a link between asthma severity and elevated serum total IgE 
(57). Also, in a more recently study from 2013, Arroyave et. al reported that increased serum 
specific IgE levels to particular indoor environmental allergens was strongly correlated with 
increased severity of asthma (75). 
 
Evidence from the current study support that levels of total IgE and atopic sensitization could 
together explain a relatively small proportion of the total variance in GI complaints, whereas 
approximately 94% of the total variance in symptom severity remains unexplained. This also 
supports that other mechanisms are involved in pathophysiology and symptom generation of 
IBS. Therefore, in future other causal factors, such as intestinal bacteria flora and fermentation 
issues, should be of interest when investigating the underlying contributory mechanisms of IBS. 
Also, the inversely association between atopic sensitization and GI complaints show that food- 
related symptoms of IBS are not mediated by specific IgE-mediated processes. Nevertheless, 
even though levels of total IgE and atopy probably play little role, the importance of other 
immunological factors such as toll-like receptors and cytokines, and its relation with gut 
microbiota should be further researched. 
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6. CONCLUSION 
 
 
 
The overall findings from our results are as follows: 
 
 
 
 
 
1. Total IgE and atopic sensitization were significantly more common in patients referred for GI 
complaints than in a general population. 
 
2. Levels of total IgE was a significant predictor of GI complaints. 
 
 
3. Atopic sensitization was inversely related to GI complaints. 
 
 
4. Together, total IgE and atopic sensitization could explain a relatively small proportion of the 
total variance in GI complaints in both patient group and the general population. 
 
5. There were no significant interaction effects by gender, age, sample or atopic sensitization in 
the association between total IgE and GI complaints. This association appeared to be consistent 
in all these subgroups. 
 
 
 
 
The findings indicating that total IgE is a consistent predictor of GI complaints are very 
interesting. Although the effect of total IgE appeared to be small, the association is considered 
highly relevant and supports a role for total IgE-related immunology in the pathophysiology of 
food related symptoms of IBS. Whether elevated levels of total IgE is related to duodenal "IgE- 
armed" mast cells remains uncertain, though it is a hypothetical possibility and should be further 
investigated. In addition, the results regarding atopic sensitization and GI complaints presented 
in this study indicate that GI symptoms self-attributed to food are not mediated by specific IgE- 
mediated processes. Consequently, biological mechanisms constituting increased levels of total 
IgE (with the exception of specific IgE) are very interesting topics for further research on the 
pathophysiology of food-related GI complaints. 
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Prosjektomtale (revidert av REK): 
REK Vest anser Helse Bergen HF som forskningsansvarlig for prosjektet. Formålet med denne studien 
er å se om det finnes en sammenhengen mellom atopisk sykdom, som pollenallergi, og mage- 
tarmproblemer blant pasienter med matoverfølsomhet. Indikasjon på atopisk sykdom er påvist blant 
mange med 
mage-tarmproblematikk. Det er derfor av interesse å se om atopi inkludert atopisk tarm og 
pollensesongen har noen innvirkning på mage-tarmplager hos disse pasientene. Pasienter som er 
henvist til Seksjon for Spesialallergologi, Yrkesmedisinsk avdeling, Haukeland universitetssykehus med 
mistanke om allergisk sykdom med og uten mage-tarm plager vil bli forespurt om å delta. Demografiske 
data, alder, kjønn og etnisk rase samt informasjoner om atopi, allergiske sykdommer og mage-tarm 
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Forskningsetisk vurdering 
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Kontrollgruppen 
En ønsker å innhente data og biologisk materiale fra en kontrollgruppe som rekrutteres gjennom en 
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grunn at prosjektene har sammenfallende problemstillinger som ikke utløser krav til nytt samtykke fra 
kontrollgruppen (jf helseforskningsloven § 15). 
 
Etnisistet 
Spørsmål om etnisitet er å anse som sensitiv informasjon. 
Komiteen legger til grunn at en i dette prosjektet har faglige og vitenskaplige grunner for å be 
om at pasientene oppgir sin etnisitet/rase. 
 
Forskningsbiobank 
Komiteen legger til grunn at det skal samles biologisk materialet og at det er behov for en 
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forskningsbiobank tilknyttet studien. Dersom det biologiske materialet ikke skal lagres etter at 
analysene er gjennomført er det ikke behov for biobank. Komiteen ber om at det opplyses om behovet 
for biobank gjennom en endringsmelding slik at den opprettede biobanken kan avvikles dersom det ikke 
er behov for den. 
 
Informasjonsskrivet 
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forutsetter at deres forskningsserver benyttes. 
Prosjektslutt er satt til 31.08.2012. Personidentifiserbare forskningsdata skal anonymiseres eller slettes 
straks det ikke lenger er behov for dem og senest 5 år etter prosjektslutt. 
 
Vedtak 
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Prosjektet skal sende sluttmelding til REK vest på fastsatt skjema senest 28.02.2013. 
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med hjemmel i helseforskningsloven § 10, jfr. forskningsetikkloven § 4. REK Vest forutsetter at dette vedtaket 
blir forelagt den forskningsansvarlige til orientering. Se helseforskningsloven § 6, jfr. § 4 bokstav e. 
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Har serum total IgE nivå noen virkning på gastrointestinale plager hos pasienter 
med selvrapportert matoverfølsomhet? 
 
 
 
 
 
Bakgrunn og hensikt 
Dette er et spørsmål til deg om å delta i en forskningsstudie for å se om det er noen sammenheng 
mellom serum total IgE nivå og mage-tarm plager hos pasienter med selvrapportert matoverfølsomhet. 
Mage-tarm plager er vanlig og ofte selv attributt til matoverfølsomhet hos generell befolkningen. Selv 
om opp til 35% av befolkningen rapporterer om unormale reaksjoner på en eller flere typer matvarer, 
så er det bare 1-3 prosent av de voksne som får diagnostisert ”ekte” matallergi. 
Selv om pasientene sjelden hadde tegn til klassisk IgE-mediert matallergi, fant vi i tidligere 
studier interessante sammenhenger knyttet til nivået av total IgE i serum. Dette var ofte høyt hos 
pasientene og pasienter med høyt total IgE hadde også ofte høyt antall mastceller med adherent IgE i 
biopsier fra tynntarmslimhinnen. Der var således en høygradig signifikant korrelasjon mellom serum 
total IgE og antall ”armerte” mastceller. Over 60% av pasientene hadde indikasjon på atopisk sykdom 
(forhøyet total IgE, funn av spesifikk IgE i serum og/eller positiv prikktest, atopisk sykehistorie som 
allergisk rhinitt, eksem, eller astma). Atopisk pasienter hadde også økt intestinal permeabilitet og høy 
antall av IgE positive celler i tynntarmslimhinnen enn ikke-atopiske pasienter. Derfor er det interessant 
å se om atopi inkludert atopisk tarm og pollensesongen har noen virkning på mage-tarm plager hos 
disse pasienter. 
Hovedhensikten med denne studien er å undersøke om det er noen sammenheng mellom serum 
total IgE nivå inkludert serum spesifikk-IgE og hudprikktest og gastrointestinale plager, og å se dens 
relasjon til pollensesongen for å identifisere atopiens rolle ved utvikling av mat-relaterte magetarm- 
plager. 
 
Hva innebærer studien? 
I løpet av ett års tid skal alle pasienter som er henvist til Seksjon for Spesialallergologi, Yrkesmedisin, 
HUS på grunn av mistanke om allergisk sykdom med og uten mage-tarm plager bli inkludert i studie. I 
tillegg skal en kontrollgruppe fra den generelle befolkningen bli inkludert. De demografiske dataene 
alder, kjønn og etisk rase fra alle pasienter og kontrollgruppe skal registreres i en database, og de vil 
delta i ”allergologiske screening” inkludert total IgE og spesifikk IgE i serum mot luftvei- og 
matvareallergener, og hudprikktest mot luftvei- og matvareallergener. Alle skal fylle ut spørreskjema 
for gradering og diagnostisering av deres mage-tarm plager. 
 
Mulige fordeler og ulemper 
Det er ingen risiko, ulemper eller ubehag ved å delta. Det eneste ubehaget kan være stikket for å ta 
blodprøve. Ellers opplever pasientene vanligvis ikke ubehag når man utfører hudprikktest. 
 
Prøvene tatt av deg og informasjonen som registreres om deg skal kun brukes slik som beskrevet i 
hensikten med studien. Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller andre 
direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og prøver gjennom en 
navneliste. Blodprøvene for rutine ”allergi screening” (total IgE, spesifikk IgE for luftvei- og matvare 
allergener) fra alle pasienter sendes rutine til LKB (Laboratoriet for Klinisk Biokjemi) ved Haukeland 
Universitetssykehus (HUS) i samme dag som de har levert blodprøve. 
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Det er kun autorisert personell (undertegnede) knyttet til prosjektet som har adgang til navnelisten og 
som kan finne tilbake til deg. 
 
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres. 
 
 
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke 
til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. Dersom du ønsker å 
delta, undertegner du samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere 
trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere ønsker å 
trekke deg eller har spørsmål til studien, kan du kontakte: 
 
Overlege, dr. med. Gülen Arslan Lied, Seksjon for Klinisk Spesialallergologi, Yrkesmedisin, HUS 
og Seksjon for Fordøyelsessykdommer, Haukeland Universitetssykehus. Telefon: 55972130 
 
 
 
Kapittel A- utdypende forklaring av hva studien innebærer 
 
 
Kriterier for deltakelse: Alle pasienter (i løpet av ett år) som er henvist til Seksjon for 
Spesialallergologi, Yrkesmedisin, HUS på grunn av mistanke om allergisk sykdom med og uten mage- 
tarm plager skal bli inkludert i studien. 
 
Bakgrunnsinformasjon om studien: Dette er en studie som man ønsker primært å undersøke om det er 
noen sammenheng mellom serum total IgE nivå inkludert serum spesifikk-IgE og hudprikktest og 
gastrointestinale plager, og å se dens relasjon med pollensesongen for å identifisere atopien rolle ved 
utvikling av mat-relaterte magetarm plager. Det er også interessant å se hvor mye atopi, tendens til 
allergiske sykdommer og mage-tarm plager som den generelle befolkningen har. 
 
Undersøkelser, blodprøver og annet: Alle pasienter og kontrollgruppe skal delta i ”allergologiske 
screening” inkludert total IgE og spesifikk IgE i serum mot luftvei- og matvareallergener, og 
hudprikktest mot luftvei- og matvareallergener. Alle skal fylle ut to spørreskjema for gradering og 
diagnostisering av deres mage-tarm plager. 
 
Tidsskjema: Studien skal utføres ila ett år, fra høst 2011 til høst 2012. 
 
Mulige fordeler: Fordeler er at resultatene kan være hjelpsom når vi behandler og informerer disse 
pasientene om sykdommen. De kan ha forståelse hvorfor plagene øker i bestemt perioder (for 
eksempel pollensesongen). På denne måten kan vi også se hvor mye atopi og tendens til allergiske 
sykdommer som den generelle befolkningen har. Vår kunnskap om mekanismen hvorfor disse 
pasienter har mage-tarm plager og hvordan atopi kan påvirke øker. 
 
Mulige bivirkninger: Det er ingen ulempe eller bivirkninger ved å delta i studien. Det kan kun være 
ubehagelig å gi blodprøve som vanlig. 
 
Pasientens/studiedeltakerens ansvar: Pasienten/studiedeltakeren eller verge vil bli orientert så raskt 
som mulig dersom ny informasjon blir tilgjengelig som kan påvirke pasientens/deltakerens villighet til 
å delta i studien. Pasienten/studiedeltakeren skal opplyses om mulige beslutninger/situasjoner som gjør 
at deres deltagelse i studien kan bli avsluttet tidligere enn planlagt. 
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Kapittel B - Personvern, biobank, økonomi og forsikring 
 
Personvern 
Opplysninger som registreres om deg er: Alder, kjønn, etniske rase, blodprøve svar (Serum total IgE, 
spesifikk IgE mot luftvei- og matvareallergener), funn fra hudprikktest og svar fra spørreskjemaene 
om dine mage-tarm plager. Alt skal registreres i database (passord beskyttet). Kun undertegnede skal 
ha tilgang til databasen. 
 
Biobank: Ingen 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver 
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om 
deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du 
trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre 
opplysningene allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner. 
 
Studien blir finansiert gjennom forskningsmidler fra Universitets i Bergen, Institutt for indremedisin. 
 
Forsikring 
Etter å ha snakket med advokat Sørli, legemiddel ansvarsforsikringen, skulle det ikke være nødvendig 
så lenge man ikke tester effekt av medisiner. 
 
Informasjon om utfallet av studien 
Pasientene kan få informasjon om både resultater av egen prøver og resultater av hele studien. 
 
 
 
Samtykke til deltakelse i studien 
 
 
 
Jeg er villig til å delta i studien 
 
 
 
---------------------------------------------------------------------------------------------------------------- 
(Signert av prosjektdeltaker, dato) 
 
 
 
Stedfortredende samtykke når berettiget, enten i tillegg til personen selv eller istedenfor 
 
 
 
 
 
 
(Signert av nærstående, dato) 
 
 
 
 
Jeg bekrefter å ha gitt informasjon om studien 
 
 
 
---------------------------------------------------------------------------------------------------------------- 
(Signert, rolle i studien, dato) 
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SPØRRESKJEMA FOR PASIENT (Kane, Am J Gastroenterol 2003) 
 
FYLT UT DATO: ………………………….. TLF NUMMER:……………………………. 
NAVN: ……………………………………… FØDSELSNR: …………………………….. 
 
* Har du mage-tarm plager ? Yes No (sett ring rundt svaret) 
 
 
 
1. IBS-KRITERIER (Sett ring rundt svaret) 
 
Spørsmål Svar 
1.1 Har du vært plaget av smerter eller ubehag i magen de siste 3 
måneder? 
 
Ja 
 
Nei 
1.2 Har du kjent disse plagene minst 1 dag/uke i 3 uker eller mer, i løpet av 
siste 3 måneder? 
 
Ja 
 
Nei 
1.3 Er avføringen uregelmessig? Ja Nei 
1.4 Har du mye luft i magen? Ja Nei 
1.5 Blir smertene/ubehaget i magen bedre etter at du har hatt avføring/fått 
tømt deg? 
 
Ja 
 
Nei 
 
 
2. IBS KRITERIER SOM GIR STØTTE FOR DIAGNOSEN  (Sett ring rundt svaret) 
 
Spørsmål Svar 
2.1 Hvis du har diaré, hender det at avføringen er fast inn i mellom? Ja Nei 
2.2 Hvis du har forstoppelse, hender det at avføringen er løs inn i mellom? Ja Nei 
2.3 Har du avføring om natta? Ja Nei 
 
2.4 Hva har du mest av? 
Diaré 
Forstoppelse 
 
 
3. KVANTITERING AV IBS SYMPTOMER 
Angis på en skala fra 0 til 10, der 0 = ingen symptomer og 10 = alvorlige symptomer 
(Kane, Am J Gastroenterol 2003) 
(Angi med tall fra 0 til 10) 
 
Spørsmål Svar 
3.1 Kvalme  
3.2 Oppblåsthet  
3.3 Magesmerter  
3.4 Forstoppelse  
3.5 Diaré  
3.6 Anoreksi (ulyst på mat)  
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4. SYMPTOMER SOM KREVER NÆRMERE VURDERING (Sett ring rundt svaret) 
 
Spørsmål Svar 
4.1 Har du gått ned i vekt det siste året? Ja Nei 
4.2 Har du sett blod i avføringen? Ja Nei 
4.3 Har du brukt antibiotika det siste året? Ja Nei 
4.4 Er det noen i din nærmeste familie som har eller har hatt kreft i 
tykktarmen? (Som nærmeste familie menes foreldre, søsken og barn.) 
 
Ja 
 
Nei 
 
 
5. FUNKSJONELL DYSPEPSI (Sett ring rundt svaret) 
 
Spørsmål Svar 
5.1 Har du hatt smerter eller ubehag ovenfor navlen? Ja Nei 
5.2 Har du kjent disse plagene høyt oppe i magen minst 1 dag/uke i 3 uker 
eller mer, i løpet av de siste 3 måneder? 
 
Ja 
 
Nei 
5.3 Blir smertene/ubehaget i øvre del av magen bedre etter at du har hatt 
avføring? 
 
Ja 
 
Nei 
 
 
6. HALSBRANN (Sett ring rundt svaret) 
 
Spørsmål Svar 
6.1 Har du hatt halsbrann eller sviende/brennende smerte bak brystbenet? Ja Nei 
6.2 Har du kjent disse plagene minst 1 dag/uke i 3 uker eller mer, i løpet av 
de siste 3 måneder? 
 
Ja 
 
Nei 
 
 
7. TILLEGGSPØRSMÅL FOR Å KARAKTERISERE ALLE PASIENTENE 
 
(Sett ring rundt svaret) 
 
Spørsmål Svar 
7.1 Har du hatt mageplagene lenger enn ett år? Ja Nei 
7.2 Har du oppsøkt lege for slike mageplager tidligere? Ja Nei 
7.3 Mener du at stress eller psykiske faktorer betyr noe for plagene dine? Ja Nei 
7.4 Er du engstelig for om plagene kan skyldes kreft eller annen alvorlig 
sykdom? 
 
Ja 
 
Nei 
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GRADERING AV MAGEPLAGER 
(Aliment Pharmacol Ther 1997; 11: 395-402) 
 
 
 
 
 
1. a)  Er du for tiden plaget med magesmerter? 
 
b) Hvis ja, hvor alvorlige er disse magesmertene? 
(Sett kryss på linjen for beskrivelsen som passer best) 
 
JA NEI 
 
Sett kryss over 
Ja eller Nei 
Ikke fyll 
ut feltene 
under: 
 
0% 100% 
Ingen Mindre Ganske Alvorlig Svært 
smerte alvorlig alvorlig  alvorlig 
 
 
c) Anslå antall dager du har smertene i løpet av en 10 dagers periode 
Eksempel: 4 betyr at du har vondt i magen i 4 av 10 dager. 
Har du vondt i magen hver dag, skriver du 10. 
 
Antall dager med smerte: x 10 
 
 
 
2. a)  Er du for tiden plaget med oppblåsthet eller stinnhet 
i magen (som du ikke forbinder med menstruasjon)? 
 
 
b) Hvis ja, hvor alvorlig er denne oppblåstheten/stinnheten? 
(Sett kryss på linjen for beskrivelsen som passer best) 
 
JA NEI 
 
Sett kryss over 
Ja eller Nei 
 
 
0%    100% 
Ingen 
oppblåsthet 
Mindre 
alvorlig 
Ganske 
alvorlig 
Alvorlig Svært 
alvorlig 
 
3. Hvor fornøyd er du med avføringsmønsteret ditt? 
(Sett kryss på linjen for beskrivelsen som passer best) 
 
 
 
0% 100% 
Svært 
fornøyd 
Ganske 
fornøyd 
Lite 
fornøyd 
Svært lite 
fornøyd 
 
4. I hvor stor grad føler du at mageplagene dine påvirker 
eller forstyrrer livet ditt? 
(Sett kryss på linjen for beskrivelsen som passer best) 
 
 
 
0% 100% 
Ikke i det  Ikke Ganske mye Fullstendig 
hele tatt særlig mye 
 
 
 
Sum 
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Table 1 and table 2 present overview of patients from patient subgroups and total patient 
group with elevated levels of specific IgE (> 0.35 kU/L) to inhalant or food allergens. 
 
 
 
Table 1: Prevalence of IgE sensitization to inhalant allergens
* 
in patients. 
 
 
 
Allergen 
Patients with GI 
complaints (n =81) 
881) 
Patients with other 
complaints (n = 80) 
Patient group 
(n = 161) 
% n % n    % n 
Dermatophagoides       
pteronyssinus 33.3 27 41.3 33  37.3 60 
Timothy 42.0 34 50.0 40  46.0 74 
Mugwort 22.2 18 16.2 13  19.3 31 
Cat 25.9 21 28.8 23  27.3 44 
Dog 35.8 29 40.0 32  37.9 61 
Horse 19.8                          16 20.0 16  19.9 32 
Birch 39.5                          32 
  3.7                            3 
40.9                  32   
  7.5                    6 
39.8 
 5.6 
65 
9 Cladosporium herbarum 
* 
Standard panels of inhalant (Phadiatop) allergens (ImmunoCAP, Phadia AB, Uppsala, Sweden). 
 
 
 
 
Table 2: Prevalence of IgE sensitization to food allergens
* 
in patients. 
 
 
 
Allergen 
Patients with GI 
complaints (n = 81) 
Patients with other 
complaints (n = 80) 
Patient group 
(n = 161) 
% n % n % n 
Wheat 13.6 11 20.0 16 15.5 25 
Cow's milk 6.2 5 10.0 8 8.1 13 
Egg white 6.2 5 8.8 7 7.5 12 
Cod 0 0 3.8 3 1.9 3 
Soy bean 8.6 7 15.0 12 11.8 19 
Peanut 12.4 10 13.2 14 14.9 24 
Hazelnut 17.3 14 26.3 21 21.7 35 
Rye 9.9 8 7.5 6 8.7 14 
Barley 13.6 11 6.3 5 9.9 16 
Oats 7.4 6 6.3 5 6.8 11 
*
Standard panels of food (fx5) allergens (ImmunoCAP, Phadia AB, Uppsala, Sweden). 
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Correlation analysis in patient subgroup with other complaints 
In our patient subgroup with GI complaints as primary cause of reference, total IgE was not 
significantly correlated with IBS-SSS (r = -.034, p = .772) or IBS-SQ (r = -.046, p = .687) 
(Figure 1, A and B). 
Figure 1: Correlation analysis in patient subgroup with GI complaints 
between A: total IgE and IBS-SSS (r = -.034, p = .772) and B: total IgE and 
IBS-SQ (r = -.046, p = .687) 
Correlation analysis in patient subgroup with other complaints 
In our patient subgroup with other complaints as primary cause of reference, the results were 
somewhat different, whereas total IgE significantly correlated with IBS-SSS (r = .241, p = 
.037), but not IBS-SQ (r = .217, p = .067) (Figure II, A and B). 
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Figure II: Correlation analysis in patient subgroup with other 
complaints between: total IgE and IBS-SSS (r = .241, p = .037) and 
B: total IgE and IBS-SQ (r = .217, p = .067). 
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Patient subgroup with GI complaints 
In patient subgroup with GI complaints as primary cause of reference, no significant 
difference in GI complaints was observed between atopic and non-atopic patients. On 
average, non-atopic patients reported more GI complaints (mean IBS-SSS = 284.09) than 
atopic (mean IBS-SSS = 255.05). However, this difference was not statistically significant (p 
= .184). This was also true when comparing IBS-SQ means, whereas non-atopic reported 
more GI complaints (mean IBS-SQ = 24.61) than atopic (mean IBS-SQ = 23.11), (p = .444). 
Figure III: Mean IBS-SSS score (left) and mean IBS-SQ score (right) between atopic and non- 
atopic in patient subgroup with GI complaints as primary cause of reference. 
Patient subgroup with other complaints 
In the patient subgroup with other allergic symptoms as primary cause of reference, the results 
was somewhat different, where atopic patients on average reported more GI complaints (mean 
IBS-SSS: 117.79) than non-atopic (mean IBS-SSS: 111.79) (p = .861) when comparing IBS- 
SSS scores, whereas non-atopic on average reported more GI complaints ( mean IBS-SQ: 
14.64) than atopic (mean IBS-SQ: 13.84) (p = .845) when comparing scores from the IBS-SQ 
scheme. However, neither of the differences in scores were significant. 
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Figure IV: Mean IBS-SSS score (left) and mean IBS-SQ score (right) between atopic and non- 
atopic in patient subgroup with other complaints as primary cause of reference. 
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Linear multivariate regression analyzes including IBS-SQ as description of GI complaints are 
presented in the following tables. 
 
 
 
 
Patient group 
 
 
Table III: Multiple regression analysis with GI complaints (IBS-SQ) as dependent variable and total IgE, 
sex, age and atopic sensitization as independent variables in patient group. Model 1 is unadjusted and 
model 2 is adjusted for atopic sensitization, sex and age. 
 
 IBS-SQ 
B 95 % CI SE b p-value 
Model 1 (unadjusted) 
 
Total IgE 
 
 
.002 
 
 
(-.002, .006) 
 
 
.002 
 
 
.311 
Model 2  
 
.003 
 
 
(-.001, .007) 
 
 
.002 
 
 
.110 
 
Total IgE 
 
Atopic sensitization* 
 
-5.051 
 
(-9.306, -.796) 
 
2.152 
 
.020 
 
Sex 
 
-3.035 
 
(-7.026, .955) 
 
2.019 
 
.135 
 
Age 
 
-.133 
 
(-.260, -.007) 
 
.064 
 
.039 
The following symbols represent: b = unstandardized beta coefficient and SE = standard error.  
Note: R
2 
= .007 for model 1, ∆R
2 
= .076 for step model 2 (p = .014). 
*Atopy was defined as having elevated specific IgE (> 0.35kU/L) to standard panels of inhalant allergens 
(phadiatop) and/or standard panels of food allergens (fx5). 
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General population 
 
 
Table IV: Multiple regression analysis with GI complaints (IBS-SQ) as dependent variable and total IgE, 
sex, age and atopic sensitization as independent variables in general population group. Model 1 is 
unadjusted and model 2 is adjusted for atopic sensitization, sex and age. 
 
 IBS-SQ 
b (95% CI) SE b p-value 
Model 1 (unadjusted) 
 
Total IgE 
 
 
.002 
 
 
(-.001, .004) 
 
 
.001 
 
 
.201 
Model 2  
 
.003 
 
 
(.000, .005) 
 
 
.001 
 
 
.057 
 
Total IgE 
 
Atopic sensitization* 
 
-1.385 
 
(-3.033, .263) 
 
.839 
 
.099 
 
Sex 
 
-1.142 
 
(-2.448, .165) 
 
.665 
 
.087 
 
Age 
 
-.044 
 
(-.141, .054) 
 
.050 
 
.381 
The following symbols represent: b = unstandardized beta coefficient and SE = standard error.  
Note: R
2 
= .004 for step 1, ∆R
2 
= .014 for step 2 (p = .079). 
*Atopy was defined as having elevated specific IgE (> 0.35kU/L) to one of the following allergens: grass, 
cat or Dermatophagoides pteronyssinus. 
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Total study population 
 
 
Table V: Multiple regression analysis of GI complaints (IBS-SQ) as dependent variable and total IgE, sex, 
age and atopic sensitization as independent variables in total study population (n = 639). Model 1 is 
unadjusted, and model 2 is adjusted for atopic sensitization, sex, age, atopic and group sample. 
 
 IBS-SQ 
b 95% CI SE b p-value 
Model 1 
 
Total IgE 
 
 
0.06 
 
 
(.004, .009) 
 
 
.001 
 
 
<.001 
Model 2  
 
.003 
 
 
(.000, .005) 
 
 
.001 
 
 
.005 
 
Total IgE 
 
Atopic sensitization* 
 
-2.734 
 
(-4.356, -1.112) 
 
.826 
 
.001 
 
Sex 
 
-1.559 
 
(-2.912, -.207) 
 
.689 
 
.024 
 
Age 
 
-.086 
 
(-.158, -.015) 
 
.036 
 
.018 
 
Patient group or general 
 
12.014 
 
(9.943, 14.084) 
 
1.054 
 
<.001 
population group 
The following symbols represent: b = unstandardized beta coefficient and SE = standard error.  
Note: R
2 
= .046 for model 1, ∆R
2 
= .293 for model 2 (p < .001). 
*Atopic sensitization was defined as having elevated specific IgE (> 0.35kU/L) to standard panels of 
inhalant allergens (phadiatop) in patient group and as having elevated specific IgE (> 0.35kU/L) to grass, 
cat or Dermatophagoides pteronyssinus in general population group. 
